Last reviewed · How we verify
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA). The secondary objectives of the study are: * To evaluate the effects of dupilumab on exacerbations in participants with ABPA * To evaluate the effects of dupilumab on ABPA-related exacerbations * To evaluate the effects of dupilumab on hospitalization/emergency department (ED)/urgent care visits in participants with ABPA * To evaluate the effects of dupilumab on asthma control in participants with ABPA * To evaluate the effects of dupilumab on health-related quality of life (HRQoL) in participants with ABPA * To evaluate the effects of dupilumab on serum total immunoglobulin E (IgE) and Aspergillus-specific IgE concentrations * To evaluate the effects of dupilumab on Fractional exhaled Nitric Oxide (FeNO) levels * To evaluate safety and tolerability of dupilumab in participants with ABPA * To evaluate dupilumab concentrations in serum and the incidence of anti-dupilumab antibodies in participants with ABPA
Details
| Lead sponsor | Regeneron Pharmaceuticals |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 62 |
| Start date | Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Feb 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Allergic Bronchopulmonary Aspergillosis
Interventions
- dupilumab
- Placebo
Countries
France, Japan, Netherlands, United Kingdom, Germany, Hungary, Poland, Romania, Bulgaria, United States